AI English summary of an SEC filing — figures as filed
CVS Health CVSThe company said total revenues for the fourth quarter and full year Q4 2023 rose to $93.8 billion, up 11.9% from the prior year, and that GAAP diluted EPS was $1.58 and Adjusted EPS was $2.12. Full-year total revenues were $357.8 billion (up 10.9%), GAAP diluted EPS was $6.47, and Adjusted EPS was $8.74.
Key points
AI summaryThe company said total revenues for the fourth quarter and full year Q4 2023 rose to $93.8 billion, up 11.9% from the prior year, and that GAAP diluted EPS was $1.58 and Adjusted EPS was $2.12. Full-year total revenues were $357.8 billion (up 10.9%), GAAP diluted EPS was $6.47, and Adjusted EPS was $8.74.
CVS Health said it revised its 2024 full-year GAAP diluted EPS guidance to at least $7.06 from at least $7.26, and its Adjusted EPS guidance to at least $8.30 from at least $8.50. It also revised its cash flow from operations guidance to at least $12.0 billion from at least $12.5 billion.
The company said the medical benefit ratio (MBR) for its Health Care Benefits segment rose to 88.5% in Q4 2023 from 85.8% a year earlier, and for the full year to 86.2% from 83.8% in 2023. It cited higher Medicare Advantage utilization as the main factor.
The company said operating cash flow for the full year 2023 was $13.4 billion, and it returned $3.1 billion to shareholders through dividends. Over the same period, it spent $16,612 million on acquisitions, net of cash and restricted cash acquired.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q4 2023 Revenue and EPS
The company said total revenues for the fourth quarter and full year Q4 2023 rose to $93.8 billion, up 11.9% from the prior year, and that GAAP diluted EPS was $1.58 and Adjusted EPS was $2.12. Full-year total revenues were $357.8 billion (up 10.9%), GAAP diluted EPS was $6.47, and Adjusted EPS was $8.74.
Source · Based on the filing body and exhibits
2024 Full-Year Outlook Revised
CVS Health said it revised its 2024 full-year GAAP diluted EPS guidance to at least $7.06 from at least $7.26, and its Adjusted EPS guidance to at least $8.30 from at least $8.50. It also revised its cash flow from operations guidance to at least $12.0 billion from at least $12.5 billion.
Source · Based on the filing body and exhibits
MBR Change in Health Care Benefits Segment
The company said the medical benefit ratio (MBR) for its Health Care Benefits segment rose to 88.5% in Q4 2023 from 85.8% a year earlier, and for the full year to 86.2% from 83.8% in 2023. It cited higher Medicare Advantage utilization as the main factor.
Source · Based on the filing body and exhibits
Full-Year Operating Cash Flow and Shareholder Returns
The company said operating cash flow for the full year 2023 was $13.4 billion, and it returned $3.1 billion to shareholders through dividends. Over the same period, it spent $16,612 million on acquisitions, net of cash and restricted cash acquired.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…